[The behavior of erythropoietin in aregenerative disorders of erythropoiesis during therapy with anabolic steroids].
D000380:Agranulocytosis / Q000188:drug therapy*; D000741:Anemia, Aplastic / Q000188:drug therapy*; D000748:Anemia, Macrocytic / Q000188:drug therapy*; D001856:Bone Marrow Examination; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D006505:Hepatitis / Q000209:etiology; D006801:Humans; D007501:Iron / Q000378:metabolism; D007504:Iron Radioisotopes; D008297:Male; D010110:Oxymetholone / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D018805:Sepsis / Q000209:etiology; D065227:Transfusion Reaction
D007504:Iron Radioisotopes; D013196:Dihydrotestosterone; D004921:Erythropoietin; D011239:Prednisolone; D007501:Iron; D010110:Oxymetholone
Zum Verhalten des Erythropoetins bei aregeneratorischen Blutbildungsstörungen unter Therapie mit anabolen Steroiden